Mondet et al. showed in a study performed on 78 bone marrow (BM) plasmas including AML, myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and healthy donors (HD), that AML patients displayed significantly higher S100A8 levels than MPN, MDS and HD [5]. Here, S100A8 is linked to myeloproliferative disorder.